- Home
- MDGL vs SRAD Comparison
MDGL vs SRAD Comparison
Compare MDGL & SRAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDGL
- SRAD
- Stock Information
- Founded
- MDGL 2011
- SRAD 2001
- Country
- MDGL United States
- SRAD Switzerland
- Employees
- MDGL N/A
- SRAD N/A
- Industry
- MDGL Biotechnology: Pharmaceutical Preparations
- SRAD Computer Software: Programming Data Processing
- Sector
- MDGL Health Care
- SRAD Technology
- Exchange
- MDGL Nasdaq
- SRAD Nasdaq
- Market Cap
- MDGL 6.1B
- SRAD 9.0B
- IPO Year
- MDGL N/A
- SRAD 2021
- Fundamental
- Price
- MDGL $417.43
- SRAD $28.93
- Analyst Decision
- MDGL Strong Buy
- SRAD Strong Buy
- Analyst Count
- MDGL 10
- SRAD 17
- Target Price
- MDGL $474.67
- SRAD $30.12
- AVG Volume (30 Days)
- MDGL 329.8K
- SRAD 1.5M
- Earning Date
- MDGL 10-30-2025
- SRAD 11-06-2025
- Dividend Yield
- MDGL N/A
- SRAD N/A
- EPS Growth
- MDGL N/A
- SRAD 359.43
- EPS
- MDGL N/A
- SRAD 0.43
- Revenue
- MDGL $515,547,000.00
- SRAD $1,399,017,029.00
- Revenue This Year
- MDGL $394.12
- SRAD $18.02
- Revenue Next Year
- MDGL $57.74
- SRAD $16.92
- P/E Ratio
- MDGL N/A
- SRAD $66.46
- Revenue Growth
- MDGL 3421.98
- SRAD 19.37
- 52 Week Low
- MDGL $200.63
- SRAD $11.72
- 52 Week High
- MDGL $457.16
- SRAD $32.22
- Technical
- Relative Strength Index (RSI)
- MDGL 54.19
- SRAD 38.74
- Support Level
- MDGL $418.36
- SRAD $29.80
- Resistance Level
- MDGL $440.90
- SRAD $30.72
- Average True Range (ATR)
- MDGL 13.63
- SRAD 0.91
- MACD
- MDGL -5.66
- SRAD -0.28
- Stochastic Oscillator
- MDGL 4.56
- SRAD 10.97
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
About SRAD Sportradar Group AG
Sportradar Group AG is a technology platform enabling next-generation engagement in sports, and a provider of B2B solutions to the sports betting industry. It generates revenue through two primary sources: subscription-based revenue and revenue sharing. Geographically, it operates in North America, Africa, AsiaPac & Middle East, Europe, and LATAM & Caribbean.